metallothionein and Cholangiocarcinoma

This study is to investigate the effect of Kruppel-like factor 9 (KLF9) on the occurrence and progression of cholangiocarcinoma (CCA) and its underlying mechanism. After the CCA cells were transfected with OE-KLF9 and/or sh-metallothionein 1 M (sh-MT1M), KLF9 and MT1M expression levels were measured. Likewise, the biological characteristics of CCA cells were measured, followed by detections of caspase3 activity and epithelial mesenchymal transition (EMT)-related protein. Furthermore, the binding site of KLF9 and MT1M was predicted and verified. An in vivo model of CCA in nude mice was established where tumor volume and weight were recorded, in addition to tumor metastasis in the liver. The expression of KLF9 and MT1M in the CCA cells was remarkably lower. CCA cells overexpressing KLF9 showed repressed abilities to proliferate, invade, and migrate, and strengthened cell apoptosis. KLF9 inhibited EMT, growth, and migration of CCA cells by modulating MT1M transcription. Additionally, KLF9 facilitated MT1M expression in vivo and improve the progression of CCA in nude mice. KLF9 acted as a transcription factor of MT1M to promote its transcription level, thereby affecting the growth and migration of CCA cells, and ultimately improving the occurrence and development of CCA.

Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Kruppel-Like Transcription Factors; Metallothionein; Mice; Mice, Nude

Cholangiocarcinoma is a common malignant tumor of digestive system. LncRNA metallothionein 1 J, pseudogene (MT1JP) has been reported to play tumor-suppressing roles in multiple cancers. However, its effect on cholangiocarcinoma has not been evaluated.. The expression of MT1JP in intrahepatic cholangiocarcinoma specimens and paired para-carcinoma tissues were detected by real-time PCR. The overexpression plasmid and siRNA of MT1JP were transfected into intrahepatic cholangiocarcinoma cells to change the expression levels of MT1JP. CCK-8, flow cytometry and transwell assays were performed to measure proliferation, cell cycle transition, apoptosis, migration and invasion. Dual-luciferase reporter assay, real-time PCR and western blot were carried out to screen the miRNA bound by MT1JP. In addition, xenograft experiment was used to determine the tumorigenesis of cholangiocarcinoma cells in nude mice.. MT1JP was downregulated in intrahepatic cholangiocarcinoma specimens, and its expression was related with TNM stage and lymph node metastasis. Overexpression of MT1JP inhibited proliferation, cell cycle transition, migration and invasion, and induced apoptosis in intrahepatic cholangiocarcinoma cells. The knockdown of MT1JP led to opposite results. MT1JP bound to miR-18a-5p to facilitate the expression of fructose-1,6-bisphosphatase 1 (FBP1). MiR-18a-5p was increased in intrahepatic cholangiocarcinoma samples, and its expression was negatively correlated with that of MT1JP. In addition, MT1JP also suppressed tumorigenesis in nude mice.. MT1JP alleviated proliferation, migration and invasion, and induced apoptosis in cholangiocarcinoma cells by regulating miR-18a-5p/FBP1 axis. These findings may provide novel insights for clinical diagnosis and treatment of cholangiocarcinoma.

Topics: Animals; Apoptosis; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Proliferation; Cholangiocarcinoma; Female; Fructose-Bisphosphatase; Gene Expression Regulation, Neoplastic; Humans; Male; Metallothionein; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Middle Aged; Prognosis; Pseudogenes; RNA, Long Noncoding; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

Metallothionein is a group of small molecular weight cysteine-rich proteins with a broad variety of functions. Metallothionein has been shown to regulate apoptosis and proliferation. Overexpression of metallothionein frequently occurs in human tumors and is related to prognosis as well as therapy response. However, metallothionein expression and its clinical relevance in cholangiocarcinoma have not been investigated. The present study aimed to analyze metallothionein over-expression and its possible prognostic impact in intrahepatic cholangiocarcinoma and hilar extrahepatic cholangiocarcinoma (Klatskin tumors). We investigated the relationship of immunohistochemically demonstrated metallothionein expression with various clinicopathological parameters in a series of 56 intrahepatic and 56 extrahepatic cholangiocarcinoma. In noncancerous bile duct epithelia metallothionein was only occasionally weakly expressed; strong metallothionein overexpression (>50% metallothionein -positive tumor cells) was noted in 7 (12.5%) of 56 intrahepatic cholangiocarcinoma and 14 (25%) of 56 Klatskin tumors, which was associated with poor clinical outcome in univariate Kaplan-Meier testing in both intrahepatic cholangiocarcinoma (P = .002) and Klatskin tumors (P = .034). Moreover, strong metallothionein expression was identified as an independent prognostic parameter in multivariate Cox regression analysis in both intrahepatic cholangiocarcinoma (P = .005) and Klatskin tumors (P = .035). In contrast, cholangiocarcinoma with a papillary phenotype (8/112; 7.1%) exhibited a significant lack of strong metallothionein expression in all 8 of 8 cases. Strong metallothionein expression is identified as an independent poor prognostic parameter, and determination of the metallothionein expression may serve as an additional tool for the therapeutic management of patients with cholangiocarcinoma. In comparison, lack of metallothionein expression seems to be associated with cholangiocarcinoma with a papillary phenotype, which is generally recognized to have a better prognosis.

Topics: Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Cholangiocarcinoma; Female; Hepatic Duct, Common; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Kaplan-Meier Estimate; Ki-67 Antigen; Klatskin Tumor; Male; Metallothionein; Middle Aged; Neoplasm Staging; Prognosis; Up-Regulation